Loading
Top

News

Scroll Down

Taking a novel approach to drug development

News

Lantern Pharma is proud to be featured in multitude of media outlets. Our goal is to crush cancer by leveraging A.I. and machine learning. By sharing our message and news, we hope to foster additional collaborations and partnerships, and engage with the clinical community in developing the right treatments for the right patients.

Artificial Intelligence in Drug Discovery and Biotech: 2022 Recap and Key Trends

November 21, 2022
Read Now
Read Now
Download Now

Powering Cancer Drug Discovery and Development Using the Artificial Intelligence and Machine Learning Platform RADR®

November 20, 2022
Read Now
Read Now
Download Now

LP-284 Shows Preclinical Activity in ATM-Mutated MCL

November 18, 2022
Read Now
Read Now
Download Now

Lantern Pharma releases positive Preclinical Data on Efficacy of LP-284 for Mantle Cell Lymphoma

October 6, 2022
Read Now
Read Now
Download Now

Highs and lows of drug repurposing

September 26, 2022
Read Now
Read Now
Download Now

Study Finds New Synthetic Lethal Agent Could Be Potential Treatment for Pancreatic Cancer

September 15, 2022
Read Now
Read Now
Download Now

Lantern Pharma Touts Encouraging Positive Efficacy For Pancreatic Cancer Candidate

September 14, 2022
Read Now
Read Now
Download Now

Lantern Pharma's New Phase 2 Clinical Trial –Harmonic™ — Approved for Launch by the FDA

July 19, 2022
Read Now
Read Now
Download Now

Lantern Pharma Gets FDA Nod to Begin Phase II Trial of LP-300 in Biomarker-Defined NSCLC

July 14, 2022
Read Now
Read Now
Download Now

Lantern Pharma: transforming oncology drug development with AI

April 14, 2022
Read Now
Read Now
Download Now

Nearly 300 Novel Agents Currently in Development for Rare Cancers

February 24, 2022
Read Now
Read Now
Download Now

This Pharma Company Is Using Machine Learning And AI To Attempt To Transform Oncology Drug Development Processes

February 2, 2022
Read Now
Read Now
Download Now

Lantern Pharma is Using Artificial Intelligence to Develop Oncology Treatments

January 28, 2022
Read Now
Read Now
Download Now

Episode 703: Panna Sharma on Leveraging Artificial Intelligence To Rescue and Develop Cancer Therapies

Action & Ambition Podcast

January 27, 2022
Read Now
Read Now
Download Now

Lantern Pharma Receives Rare Pediatric Disease and Orphan Drug Designations for LP-184 for the Treatment of Atypical Teratoid Rhabdoid Tumor (ATRT)

January 24, 2022
Read Now
Read Now
Download Now

Lantern Pharma Collaborating With Danish Cancer Research Center on Drugs for NER-Deficient Tumors

January 18, 2022
Read Now
Read Now
Download Now

Lantern Pharma and NCI expand oncology partnership

January 13, 2022
Read Now
Read Now
Download Now

Lantern Pharma rises 9% on team up with National Cancer Institute for drug candidates

January 12, 2022
Read Now
Read Now
Download Now

Lantern Pharma (LTRN) Reports Positive Efficacy Data of LP-284 in Hematologic Cancers

December 14, 2021
Read Now
Read Now
Download Now

What is the Real Cost of Developing Medicine?

Healthcare Americana Podcast

December 6, 2021
Read Now
Read Now
Download Now

Cost of Care: Defanged drug pricing reform means less of a bite for Big Pharma

November 17, 2021
Read Now
Read Now
Download Now

The Local Oncology Innovator ‘Smashing’ Drug Development Timelines

November 8, 2021
Read Now
Read Now
Download Now

Why we are on the cusp of a golden age of medicine

November 2, 2021
Read Now
Read Now
Download Now

The AI Pharmacist: How Artificial Intelligence Can Accelerate Drug Development

October 20, 2021
Read Now
Read Now
Download Now

Slice of Healthcare Podcast #192 – Panna Sharma, CEO & President at Lantern Pharma

September 24, 2021
Read Now
Read Now
Download Now

How Technologies Like AI and Machine Learning Can Help With the Development of Medicine

TradeTalks Video Broadcasts - With Jill Malandrino

September 22, 2021
Read Now
Read Now
Download Now

BioBoss Podcast #39 - Panna Sharma, CEO of Lantern Pharma

September 12, 2021
Read Now
Read Now
Download Now

Biotech is sprouting into Dallas-Fort Worth’s next big thing, based on seeds planted decades ago

September 2, 2021
Read Now
Read Now
Download Now

Join our team and help transform the cancer drug development process, cost and timeline!

August 26, 2021
Read Now
Read Now
Download Now

Behind the Study: Retaining Nanomolar Potency in Lung Cancer

August 16, 2021
Read Now
Read Now
Download Now

Lantern Pharma CEO Shares His Four Secrets to Turning a Startup into an IPO

August 3, 2021
Read Now
Read Now
Download Now

Benzinga's Power Hour Show

July 30, 2021
Read Now
Read Now
Download Now

How AI Is Expediting Medicine Development

July 28, 2021
Read Now
Read Now
Download Now

Allarity Therapeutics, Lantern Pharma Enter into Agreement for Future Clinical Development of Irofulven

July 26, 2021
Read Now
Read Now
Download Now

Dallas region sees growing traction around the life sciences amid IPOs, fundings

July 22, 2021
Read Now
Read Now
Download Now

Preclinical Data on New Pancreatic Cancer Drug Shines with over 90% Efficacy

July 20, 2021
Read Now
Read Now
Download Now

Midday Hot Stocks: SPCE falls as Bezos flies; HAL, UBS rise on earnings; LTRN gets strong pre-clinical data

July 20, 2021
Read Now
Read Now
Download Now

How AI Is Transforming the Healthcare Landscape & Accelerating the Development of Medicine

July 9, 2021
Read Now
Read Now
Download Now

Lantern Pharma and Actuate Therapeutics Announce Research & Development Collaboration Leveraging Lantern’s Artificial Intelligence Platform

May 3, 2021
Read Now
Read Now
Download Now

Lantern Pharma’s Proprietary A.I. Platform for Precision Oncology Drug Development, RADR®, Surpasses 4.6 Billion Datapoints, Accelerating the Company’s Progress in the Development of Biopharma Collaborations and Partnerships and Advancing

April 29, 2021
Read Now
Read Now
Download Now

New Lantern Manuscript: The acylfulvene alkylating agent, LP-184, retains nanomolar potency in non-small cell lung cancer carrying otherwise therapy-refractory mutations

April 13, 2021
Read Now
Read Now
Download Now

Lantern ($LTRN) Announces Filing of Seven Patent Applications Globally on Novel DNA-Damaging Agent with

March 17, 2021
Read Now
Read Now
Download Now

A machine learning‐based gene signature of response to the novel alkylating agent LP‐184 distinguishes its potential tumor indications

March 4, 2021
Read Now
Read Now
Download Now

Technology Is Rapidly Changing Cancer Care

January 23, 2021
Read Now
Read Now
Download Now

AI offers promise but faces barriers in drug development

December 10, 2020
Read Now
Read Now
Download Now

Dallas’ Lantern Pharma Hits Major Milestone on its AI Platform to Advance its Oncology Drug Research and Development

November 18, 2020
Read Now
Read Now
Download Now

Episode 68: Rocking Garage Biotech

October 29, 2020
Read Now
Read Now
Download Now

What going public means for Lantern Pharma

September 29, 2020
Read Now
Read Now
Download Now

Lantern Pharma, Fox Chase Partner on Pancreatic Cancer Drug, Search for Predictive Gene Signature

September 23, 2020
Read Now
Read Now
Download Now